Drug intelligence / Profile preview

177Lu-TR0471

Development stage: Unknown
Lead developer: Tongrui Biopharmaceutical
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-TR0471 is a PSMA-targeted radiopharmaceutical developed by Tongrui Biopharmaceutical (Chengdu) Co., Ltd. for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It consists of a targeting ligand (TR0471) that binds with high affinity to Prostate-Specific Membrane Antigen (PSMA), which is overexpressed on the surface of prostate cancer cells. The ligand is conjugated to the beta-emitting radioisotope Lutetium-177 (177Lu). Upon binding to PSMA-positive cells, the compound is internalized, and the localized beta radiation from 177Lu induces DNA damage and cell death in the tumor cells and the surrounding microenvironment. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with advanced prostate cancer.

Other names: Lutetium (177Lu) TR0471Lutetium Lu 177 TR0471

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 177Lu-TR0471.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-TR0471.

Explore the full profile